Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Earnings In Brief

This article was originally published in The Gray Sheet

Executive Summary

CryoCath's AF results: Arctic Front cryoablation system with FlexCath deflectable sheath to treat atrial fibrillation achieved a chronic efficacy rate of over 80% at 6 months in a 20-patient U.S. trial, according to CryoCath CEO Steve Arless. The firm reported no long-term safety issues, though two patients did have to be re-treated early on. "If the data continue to build as with the first 20 patients, we'll certainly corner the vast majority of the [atrial fibrillation] market. But the interesting thing we will address longer term is what role [Arctic Front] will play in the treatment of ventricular tachycardia, where implantable defibrillators play a huge role right now," Arless said. For the quarter ended Dec. 31, the firm reported revenue of $8.9 mil., up 48% over the prior-year period...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT023238

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel